ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix
News provided by
Share this article
Share this article
EAST WINDSOR, N.J., Feb. 19, 2021 /PRNewswire/ ForDoz Pharma has entered into an agreement with LipoMedix for manufacturing its lead compound, pegylated liposomal Promitil
® (PL-MLP) for a Phase 2 clinical study.
Promitil s unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy. In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug resistant tumors.